The decoding of the proteome is revolutionizing the way diseases are diagnosed, treated, and prevented. Biognosys invents and provides patented proteomics solutions at the quality, scale, and speed required to transform R&D, clinical trials, and clinical decision making.
Biognosys is the world leader in next-generation proteomics contract research services to support pharma and biotech research and clinical development.
Our software solutions for proteomics include Spectronaut® for DIA proteomics, SpectroDive™ for Targeted Proteomics, SpectroMine™ for DDA proteomics, and our free-of-charge QC tool QuiC™.
New strategic partnership aims to broaden access to Biognosys’ leading CRO services and Spectronaut® software tools for unbiased proteomics and epiproteomics, expected to[...]READ MORE
Spectronaut 17 features directDIA+™, the best-performing library-free workflow for DIA proteomics available on the[...]READ MORE
Biognosys opens US offices in Cambridge (MA) with ribbon cutting ceremony, champagne mixer, and vast scientific program featuring collaborators NeoGenomics, and[...]READ MORE
Biognosys, a leader in next-generation proteomics solutions for drug discovery and development, announced today that they are participating in the ALDA (Analytical, Life Science[...]READ MORE
The expansion is part of the company’s growth strategy for North America and will foster collaboration with life science companies and academia. An inauguration event will take[...]READ MORE
Biognosys announced today that they are participating in the upcoming Capital One Spatial Biology & Proteomics Healthcare Disruptors Summit, taking place virtually on Wednesday,[...]READ MORE
SpectroDive 11 makes your targeted proteomics analysis easer than[...]READ MORE
Spectronaut®, our flagship software for DIA proteomics analysis, recently turned 10! To celebrate this milestone and the release of Spectronaut 16, we are offering all new[...]READ MORE
Access our knowledge base with relevant resources and guiding information.